{
  "id": 18604259,
  "title": "Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence",
  "url": "https://urgent.news/2026/11/07/eli-lilly-is-much-more-than-a-weight-loss-drug-company-heres-the",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T00:18:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/06/eli-lilly-is-much-more-than-a-weight-loss-drug-company-here-s-the-evidence/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly (LLY) is more than just a weight-loss drug company, as evidenced by its latest third-quarter earnings update. The company's impressive growth was driven by its weight loss medicine, Zepbound, which saw a 49% increase in revenue to $5.4 billion year-over-year, and Mounjaro, an anti-obesity drug, which increased sales by 65% to $10.7 billion. Together, these two medications accounted for 66% of Eli Lilly's total revenue, which itself rose 39% year-over-year to $24.4 billion.\n\nHowever, Eli Lilly's success extends beyond its GLP-1 portfolio. The company boasts several promising products in various therapeutic areas that could become blockbuster treatments in the future. For instance, Kisunla, a potential Alzheimer's disease treatment, has recently received a label expansion for first-line treatment of certain patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Ebglyss, a medication for atopic dermatitis (eczema), received a label expansion for maintenance dosing every eight weeks, making it more convenient for patients. Omvoh, which treats ulcerative colitis, also received a label expansion. Lastly, Kisunla, an Alzheimer's disease drug, has entered a market with few treatment options and a large addressable opportunity due to the world's aging population.\n\nThese additional medications, alongside Eli Lilly's deep pipeline of promising drugs like Inluriyo, an investigational cancer treatment, and remternetug, a potential Alzheimer's disease drug, demonstrate the company's diversification beyond its core weight-loss therapy. As Eli Lilly continues to expand its portfolio and face increased competition in its GLP-1-focused area, it is well-positioned for continued growth and success in the medium term.",
  "summary": "Eli Lilly could thrive even as competition in the weight-loss market intensifies.",
  "key_points": [
    "Eli Lilly's revenue grew 39% to $24.4 billion in Q3 2023",
    "Weight-loss drugs Zepbound and Mounjaro drove 66% of revenue growth",
    "Company's pipeline includes potential Alzheimer's, eczema, and ulcerative colitis treatments"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence",
        "url": "https://urgent.news/2026/11/07/eli-lilly-is-much-more-than-a-weight-loss-drug-company-heres-the-18605409",
        "published": "2026-11-07T00:38:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}